Frazier Financial Advisors LLC Has $29,000 Stake in Smith & Nephew plc (NYSE:SNN)

Frazier Financial Advisors LLC reduced its holdings in Smith & Nephew plc (NYSE:SNN) by 37.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,190 shares of the medical equipment provider’s stock after selling 708 shares during the period. Frazier Financial Advisors LLC’s holdings in Smith & Nephew were worth $29,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the business. Principal Securities Inc. lifted its stake in shares of Smith & Nephew by 87.6% in the 4th quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 691 shares during the period. R Squared Ltd acquired a new position in Smith & Nephew in the fourth quarter valued at about $41,000. Hara Capital LLC boosted its holdings in Smith & Nephew by 391.4% during the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 1,957 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Smith & Nephew by 31.8% during the fourth quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider’s stock worth $73,000 after purchasing an additional 718 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in Smith & Nephew by 26.0% during the fourth quarter. Blue Trust Inc. now owns 5,871 shares of the medical equipment provider’s stock worth $144,000 after acquiring an additional 1,213 shares in the last quarter. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew Trading Up 0.0 %

Shares of NYSE:SNN opened at $28.42 on Friday. Smith & Nephew plc has a 52-week low of $23.65 and a 52-week high of $31.72. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. The company has a market capitalization of $12.43 billion, a P/E ratio of 13.16, a price-to-earnings-growth ratio of 1.26 and a beta of 0.83. The company has a 50-day simple moving average of $27.07 and a 200 day simple moving average of $27.02.

Smith & Nephew Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Wednesday, May 28th. Investors of record on Friday, March 28th will be issued a dividend of $0.447 per share. The ex-dividend date is Friday, March 28th. This is a positive change from Smith & Nephew’s previous semi-annual dividend of $0.29. This represents a dividend yield of 2.5%. Smith & Nephew’s payout ratio is presently 41.20%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. StockNews.com raised Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 26th. Canaccord Genuity Group reiterated a “hold” rating and issued a $27.00 price target on shares of Smith & Nephew in a research note on Monday, March 17th. Finally, UBS Group downgraded shares of Smith & Nephew from a “buy” rating to a “neutral” rating in a research note on Wednesday, March 12th. Four analysts have rated the stock with a hold rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $27.00.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.